Adding to these data, cabergoline, a first-line treatment for lactotroph adenomas, was recently shown to suppress the prolactin hypersecretion and reduce the tumor size via the mTOR inhibition pathway in a rat pituitary tumor [143]. This evidence concerns the gene PRL and prolactin-producing pituitary gland adenoma.